Non-Viral Drug Delivery Systems Market Forecast 2026–2035: How to Leverage Market Growth
Uncover key drivers, emerging technologies, and competitive movements shaping the non-viral drug delivery systems market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the Non-Viral Drug Delivery Systems Market be in 2030 compared with 2026?
The non-viral drug delivery systems market size has seen swift expansion in recent years. This market is forecasted to grow from $9.84 billion in 2025 to $11.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.4%. The historical period’s growth can be ascribed to factors including the reliance on viral delivery methods, limited understanding of non-viral techniques, the emergence of biologics development, the establishment of initial regulatory frameworks for drug delivery, and an early academic focus on nanoparticles.
The non-viral drug delivery systems market is projected for swift expansion in the coming years, with its size expected to reach $19.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.1%. This growth during the forecast period is fueled by advancements in polymer-based carriers, the increasing prevalence of RNA and DNA therapeutics, a surge in investment in personalized medicine, the expanding operations of contract development and manufacturing organizations (CDMOs), and enhanced collaborations between pharmaceutical companies and academic institutions. Noteworthy trends anticipated during this period involve the increasing adoption of non-viral delivery platforms for targeted therapies, a rise in the use of nanoparticles and liposome-based carriers, a concentrated effort on reducing immune responses and boosting safety, the continued development of personalized medicine and targeted therapeutics, and the expansion of CDMOs and academic research partnerships.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
What Drivers Are Guiding Growth Patterns In The Non-Viral Drug Delivery Systems Market?
The non-viral drug delivery systems market is set to experience growth due to the escalating demand for personalized medicines. This medical approach involves tailoring treatment to an individual’s unique genetic makeup, lifestyle, and environment. The rising need for personalized medicine stems from its ability to provide more effective treatments by targeting the specific causes of disease in each patient. Non-viral systems facilitate personalized medicine by safely delivering drugs or genes to cells, thereby mitigating risks and improving treatment precision. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, an increase from 6 approvals in 2022. Therefore, the increasing demand for personalized medicines is a key driver for the expansion of the non-viral drug delivery systems market.
Which Segments Are Driving Activity In The Non-Viral Drug Delivery Systems Market?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
What Trends Are Expected To Impact The Competitive Landscape Of The Non-Viral Drug Delivery Systems Market?
Leading companies within the non-viral drug delivery system market are prioritizing advanced technologies like pre-optimized ionizable lipid mix systems to enhance the development and distribution of RNA-based therapeutics. A pre-optimized ionizable lipid mix system serves as a formulation technology that enables the effective encapsulation of RNA molecules into lipid nanoparticles, guaranteeing high stability, payload protection, and precise delivery for gene-based drug applications. For instance, in September 2024, Cytiva, a US-based biotechnology company, launched an RNA delivery LNP kit designed for compatibility with its NanoAssemblr Ignite and Ignite+ platforms. This system features a ready-to-use ionizable lipid mix, which allows for rapid screening of RNA payloads and validation of effective delivery, especially pertinent in the context of infectious disease vaccine development. It integrates smoothly with automated microfluidic platforms, supports scalable manufacturing through its GMP-grade components, and provides protocols and proof-of-concept data to guide users from early discovery phases to clinical evaluation.
Which Major Firms Are Strengthening Their Position In The Non-Viral Drug Delivery Systems Market?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Shows The Strongest Potential For Future Expansion In The Non-Viral Drug Delivery Systems Market?
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Non-Viral Drug Delivery Systems Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24628&type=smp
Browse Through More Reports Similar to the Global Non-Viral Drug Delivery Systems Market 2026, By The Business Research Company
Advanced Drug Delivery Systems Market Report 2026
Electronic Drug Delivery Systems Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
